INBX Inhibrx Biosciences, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2007919 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY550.0%
TTM net income YoY-108.3%
TTM EPS YoY-108.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-10,386.5%
Net margin-10,773.5%
FCF margin-9,986.5%
EBITDA margin-10,195.5%
Returns
ROE-197.8%
ROA-85.6%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets94.5%
Debt / equity12.58x
Current ratio3.93x
Interest coverage-11.07x
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-6.3%
Payout ratio—
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.00M | $0 | — | $0 | $0 | $1.30M | $0 | $100,000 |
| R&D expense | $25.97M | $23.90M | $25.22M | $25.35M | $28.54M | $22.27M | $36.88M | $33.37M |
| SG&A expense | $7.77M | $8.25M | $5.71M | $5.57M | $5.28M | $6.42M | $6.02M | $16.66M |
| Operating income | -$31.73M | -$32.15M | -$30.93M | -$30.92M | -$33.81M | -$27.39M | -$42.90M | -$49.93M |
| Interest expense | $8.75M | $5.69M | $3.51M | $3.19M | $3.18M | $3.14M | $2.69M | $0 |
| Pretax income | -$38.73M | -$36.65M | -$33.44M | -$32.83M | -$35.26M | -$28.65M | -$43.31M | -$47.87M |
| Income tax | $0 | $3,000 | $0 | $0 | $0 | $2,000 | $0 | $0 |
| Net income | -$38.73M | -$36.65M | -$33.44M | -$32.83M | -$35.26M | -$28.65M | -$43.31M | -$47.87M |
| EBITDA | -$31.22M | -$31.63M | -$30.39M | -$30.36M | -$33.23M | -$26.73M | -$42.23M | -$49.24M |
| EPS (basic) | -2.46 | -2.34 | -2.15 | — | -2.28 | -1.85 | -2.80 | — |
| EPS (diluted) | -2.46 | -2.34 | -2.15 | — | -2.28 | -1.85 | -2.80 | — |
| Weighted avg. shares (diluted) | 15.72M | 15.67M | 15.59M | — | 15.48M | 15.47M | 15.47M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $199.47M | $133.34M | $161.66M | $124.22M | $153.09M | $186.57M | $216.52M | $152.60M |
| Current assets | $206.87M | $142.21M | $171.34M | $132.83M | $161.42M | $193.96M | $223.39M | $160.40M |
| PP&E, net | $2.17M | $2.69M | $3.20M | $3.73M | $4.31M | $4.88M | $5.55M | $6.20M |
| Total assets | $220.29M | $154.22M | $183.97M | $146.48M | $177.47M | $212.12M | $242.64M | $180.77M |
| Current liabilities | $27.30M | $28.06M | $26.51M | $33.80M | $35.98M | $38.94M | $43.64M | $40.73M |
| Long-term debt | $276.70M | $176.28M | $174.99M | $100.56M | $99.92M | $99.28M | $98.65M | $0 |
| Total debt | $276.70M | $176.28M | $174.99M | $100.56M | $99.92M | $99.28M | $98.65M | $0 |
| Total liabilities | $306.17M | $207.20M | $205.00M | $138.49M | $140.64M | $143.56M | $148.20M | $47.18M |
| Shareholders' equity | -$85.88M | -$52.98M | -$21.04M | $7.99M | $36.83M | $68.56M | $94.44M | $133.58M |
| Net debt | $77.23M | $42.94M | $13.34M | -$23.66M | -$53.17M | -$87.29M | -$117.87M | -$152.60M |
| Shares outstanding | 14.76M | 14.71M | 14.61M | 14.58M | 14.50M | 14.48M | 14.48M | 14.48M |
| Cash flow statement | ||||||||
| Operating cash flow | -$34.60M | -$29.92M | -$38.03M | -$30.12M | -$33.82M | -$29.95M | -$35.90M | -$43.72M |
| Capital expenditure | $29,000 | $0 | $0 | $0 | $10,000 | $0 | $21,000 | $16,000 |
| Free cash flow | -$34.63M | -$29.92M | -$38.03M | -$30.12M | -$33.83M | -$29.95M | -$35.92M | -$43.74M |
| Investing cash flow | -$29,000 | $0 | $0 | $0 | -$7,000 | $0 | -$21,000 | -$16,000 |
| Financing cash flow | $100.76M | $1.60M | $75.46M | $1.25M | $352,000 | $0 | $99.84M | $0 |
| Depreciation & amortization | $514,000 | $523,000 | $537,000 | $564,000 | $582,000 | $662,000 | $675,000 | $689,000 |
| Stock-based compensation | $3.34M | $3.10M | $2.65M | $2.74M | $3.17M | $2.77M | $2.45M | $2.98M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.